Myriad Genetics (MYGN) Equity Average (2011 - 2026)

Myriad Genetics (MYGN) has 16 years of Equity Average data on file, last reported at $352.7 million in Q1 2026.

• Equity Average for Q1 2026 came in at $352.7 million, down 49.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $352.7 million (down 49.83% YoY), and the FY2025 annual result was $534.6 million, down 27.97% from the prior year.
• Equity Average eased to $352.7 million in Q1 2026 per MYGN's latest filing, from $370.4 million in the prior quarter.
• Over five years, Equity Average peaked at $959.0 million in Q1 2022 and troughed at $352.7 million in Q1 2026.
• A 5-year average of $715.1 million and a median of $736.1 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2026: Equity Average increased 9.21% in 2022, then slumped 49.83% in 2026.
• A 5-year view of Equity Average shows it stood at $901.2 million in 2022, then declined by 18.63% to $733.3 million in 2023, then decreased by 2.3% to $716.4 million in 2024, then tumbled by 48.3% to $370.4 million in 2025, then slipped by 4.78% to $352.7 million in 2026.
• Business Quant data shows MYGN's Equity Average at $352.7 million in Q1 2026, $370.4 million in Q4 2025, and $380.4 million in Q3 2025.